Clinical Trial Update: Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1 [Phase 4]

View source ↗

Summary

Phase 4 trial investigating mechanisms behind the hypotensive response to ARB/NEP inhibition; the study NCT03738878 was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Sacubitril/valsartan (Entresto) (sacubitril/valsartan)

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: Hypertension | Phase 4 | Status: TERMINATED | Results posted: 2025-08-03